1. Araki E, et al. Effects of pemafibrate, a novel selective PPARα modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia. A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2018; 41: 538–546.
2. Azdaki N, et al. Comparison between homocysteine, fibrinogen, PT, PTT, INR and CRP in male smokers with/without addiction to opium. Addict Health 2017; 9: 17–23.
3. Bergstra SA, et al. Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents. RMD open 2017; 3: e000568.
4. Bremander A, et al. The educational needs of patients with undifferentiated spondyloarthritis. Validation of the ENAT questionnaire and needs assessment. Musculoskeletal Care 2018; 16: 313–317.
5. Elam MB, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2017; 2: 370–380.